Literature DB >> 11244499

Overexpression of p97Eps8 leads to cellular transformation: implication of pleckstrin homology domain in p97Eps8-mediated ERK activation.

M C Maa1, C Y Hsieh, T H Leu.   

Abstract

Two isoforms of Eps8, p97Eps8 and p68Eps8, have been identified as the substrates for receptor tyrosine kinases. Our previous studies indicated that both tyrosyl phosphorylation and protein expression of Eps8 were elevated in v-Src transformed cells. In an attempt to examine the role played by p97Eps8 in tumorigenesis, we have first obtained cells overexpressing p97Eps8 and its pleckstrin homology (PH)-truncated variant. We then demonstrated that cells overexpressing p97Eps8 not only exhibited the ability of focus formation in cell culture but also promoted the tumor formation in mice as compared to controls. Furthermore, elevated serum-induced extracellular responsive kinase (ERK) activation was observed in p97Eps8 overexpressors. This enhanced ERK activation was sensitive to a MEK1 specific inhibitor PD98059 and was important for p97Eps8-mediated transformation, since transfection of vectors expressing dominant negative MEK1 and p97Eps8 abrogated focus formation by p97Eps8. In contrast, PH-truncated p97Eps8 failed to localize at the plasma membrane and that the truncated variant also did not elevate ERK activation and cellular transformation in response to serum stimulation. Our results thus indicated that: (i) the gene encoding p97Eps8 was an oncogene; (ii) p97Eps8-induced oncogenesis was partly mediated by ERK activation; and (iii) the PH domain of p97Eps8 was critical for its cellular localization, ERK activation and its ability to transform cells. Oncogene (2001) 20, 106 - 112.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244499     DOI: 10.1038/sj.onc.1204069

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Eps8 protein facilitates phagocytosis by increasing TLR4-MyD88 protein interaction in lipopolysaccharide-stimulated macrophages.

Authors:  Yen-Jen Chen; Ming-Yu Hsieh; Miao Ying Chang; Hui-Chen Chen; Ming-Shiou Jan; Ming-Chei Maa; Tzeng-Horng Leu
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

2.  Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells.

Authors:  Christina Schoenherr; Bryan Serrels; Charlotte Proby; Debbie L Cunningham; Jane E Findlay; George S Baillie; John K Heath; Margaret C Frame
Journal:  J Cell Sci       Date:  2014-10-29       Impact factor: 5.285

3.  A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.

Authors:  Yiran Chen; Xiaoling Xie; Anqin Wu; Lei Wang; Yuxing Hu; Honghao Zhang; Yuhua Li
Journal:  J Exp Clin Cancer Res       Date:  2018-01-22

4.  FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.

Authors:  Qiang Wen; Xinwei Jiao; Fei Kuang; Beibei Hou; Yajing Zhu; Wenyu Guo; Guangxin Sun; Yufeng Ba; Dandan Yu; David Wang; Faya Zhang; Hui Chao Qiao; Shuolin Wang; Shu Tang; Hailing Qiao
Journal:  EBioMedicine       Date:  2019-02-07       Impact factor: 8.143

5.  Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review).

Authors:  Kaili Luo; Lei Zhang; Yuan Liao; Hongyu Zhou; Hongying Yang; Min Luo; Chen Qing
Journal:  Oncol Rep       Date:  2021-01-07       Impact factor: 3.906

6.  SCFFbxw5 mediates transient degradation of actin remodeller Eps8 to allow proper mitotic progression.

Authors:  Achim Werner; Andrea Disanza; Nina Reifenberger; Gregor Habeck; Janina Becker; Matthew Calabrese; Henning Urlaub; Holger Lorenz; Brenda Schulman; Giorgio Scita; Frauke Melchior
Journal:  Nat Cell Biol       Date:  2013-01-13       Impact factor: 28.824

7.  EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.

Authors:  Rui Huang; Huimin Liu; Yiran Chen; Yanjie He; Qian Kang; Sanfang Tu; Yingzhi He; Xuan Zhou; Lei Wang; Jilong Yang; Anqin Wu; Yuhua Li
Journal:  Oncol Rep       Date:  2017-11-20       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.